Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 7/20 | 0.36 |
| ▸ | CLK3 | P49761 | 7/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.36 |
| ▸ | PIP5K1C | O60331 | 4/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.34 |
| ▸ | ITK | Q08881 | 3/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | MC5R | P33032 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13655344 | 0.88 | CHEK1 (0.37) | CLK2CLK3DYRK1APIP5K1CCHEK1 | |
| SCHEMBL13655340 | 0.86 | VCP (0.39) | CLK2CLK3DYRK1APIP5K1CITK | |
| SCHEMBL13655339 | 0.80 | CHEK1 (0.49) | CLK2CLK3DYRK1ACHEK1 | |
| SCHEMBL13655325 | 0.80 | MC4R (0.40) | PIP5K1CCHEK1MC4RMC5R | |
| SCHEMBL13655332 | 0.72 | PIP5K1C (0.40) | PIP5K1CCHEK1 | |
| SCHEMBL13655330 | 0.70 | CLK2 (0.39) | CLK2CLK3DYRK1APIP5K1CCHEK1 | |
| SCHEMBL13655342 | 0.69 | TERT (0.41) | CLK2CLK3DYRK1APIP5K1CCHEK1 | |
| SCHEMBL13655331 | 0.66 | KDM4E (0.43) | PIP5K1CCHEK1ITK | |
| SCHEMBL13655335 | 0.66 | PIP5K1C (0.44) | PIP5K1CCHEK1ITK | |
| SCHEMBL13655336 | 0.65 | CHEK1 (0.46) | PIP5K1CCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MAPT, PSEN2, PSEN1 | CLK2 685/4885CLK3 1342/4885DYRK1A 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.